Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01219777 · ClinicalTrials.gov registry record · Phase 1

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

A Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Ritu Salani.

Completed
Registry status
Phase 1
Development phase
9
Enrollment target
1
Study location

NCT01219777 is a Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer that has completed, run by Ritu Salani. The registered enrollment target is 9 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01219777, a Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, has completed, sponsored by Ritu Salani.

COMPLETED
Registry status
Phase 1
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of intravenous weekly paclitaxel given with intravenous carboplatin and bevacizumab in patients with epithelial ovarian, primary peritoneal, or fallopian tube carcinoma that are to receive neoadjuvant chemotherapy (prior to surgical cytoreduction). Patients will then undergo surgery which will allow an objective measure of response to the above regimen as well as assessment of surgical outcomes.

Conditions Studied

Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer

Interventions

  • DRUG Bevacizumab
  • DRUG Paclitaxel
  • DRUG carboplatin

Study Locations (1)

Ohio

  • The Ohio State University Medical Center - Columbus

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2010-09
Est. Completion 2015-05
Phase Phase 1

Sponsor

Ritu Salani

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01219777

The ClinicalTrials.gov registry entry for NCT01219777 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Ritu Salani, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.

NCT01219777 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT01219777 about?

NCT01219777 is a clinical study titled "Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian". The purpose of this study is to determine the maximum tolerated dose (MTD) of intravenous weekly paclitaxel given with intravenous carboplatin and bevacizumab in patients with epithelial ovarian, primary peritoneal, or fallopian tube carcinoma that are to receive neoadjuvant chemotherapy (prior to s...

What is the current status of trial NCT01219777?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2010-09. Estimated completion is 2015-05.

What conditions does trial NCT01219777 study?

This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.

What interventions are being tested in trial NCT01219777?

The interventions under investigation include: Bevacizumab (DRUG), Paclitaxel (DRUG), carboplatin (DRUG).

Who is sponsoring clinical trial NCT01219777?

This trial is sponsored by Ritu Salani, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01219777 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Cancer

All registered trials for this condition

Fallopian Tube Cancer

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.